TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Rafferty Asset Management LLC

Rafferty Asset Management LLC reduced its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 2.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 331,412 shares of the biopharmaceutical company's stock after selling 9,057 shares during the period. Rafferty Asset Management LLC owned about 0.21% of TG Therapeutics worth $9,976,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bleakley Financial Group LLC acquired a new stake in TG Therapeutics in the fourth quarter valued at $245,000. Castellan Group bought a new stake in shares of TG Therapeutics in the 4th quarter worth about $8,539,000. Barclays PLC boosted its holdings in TG Therapeutics by 83.9% in the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock worth $8,117,000 after purchasing an additional 158,323 shares during the period. Stratos Wealth Advisors LLC acquired a new position in TG Therapeutics in the fourth quarter worth $241,000. Finally, Strategic Financial Concepts LLC bought a new stake in TG Therapeutics during the fourth quarter valued at $1,404,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on TGTX shares. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a report on Tuesday, March 4th. Wall Street Zen raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $40.80.

TG Therapeutics Stock Performance

TGTX stock traded up $0.14 during mid-day trading on Thursday, reaching $34.34. The company had a trading volume of 469,542 shares, compared to its average volume of 2,983,550. The stock's 50-day simple moving average is $38.38 and its two-hundred day simple moving average is $34.09. The stock has a market capitalization of $5.45 billion, a P/E ratio of -344.16 and a beta of 2.21. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a one year low of $15.16 and a one year high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). The firm had revenue of $120.86 million during the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company's revenue for the quarter was up 90.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.07) earnings per share. Research analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.